The OBR (Office for Budget Responsibility) anticipates economic output in Britain to expand by 1.8% in 2026 and by 1.5% in ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...

Sarepta will discontinue its next generation of exon-skipping drugs for Duchenne muscular dystrophy over safety concerns, in ...

Shares of AstraZeneca dropped more than 7% yesterday after the Chinese publication Yicai Global reported that dozens of ...

Key Takeaways Zacks earnings estimates for AstraZeneca are currently at $4.06 per share. However, the earnings picture ...

It’s fair to say that there’s a lot going on which isn’t related to earnings or drug development ... stocks that investors should consider buying. Want to see if AstraZeneca made the list? The ...

Greetings and welcome to I US third quarter, 2024 earnings conference call. (Operators Instructions). I would now like to turn the conference over to your host, Jordan Shapiro. Thank you. You may ...

AbbVie is reaching for the Sky(rizi) as it spent a staggering $51.5 million on TV drug ads for its immunology blockbuster in October. | AbbVie is reaching for the Sky(rizi) as it spent a staggering ...

These are still high on the list of AZ’s core focus today ... to have paid off – between 2005 and 2010 AstraZeneca‘s success rates for taking drugs from candidate nomination to phase ...

Powerful weight-loss drugs like Wegovy and Zepbound have driven nearly $1 trillion in market-capitalization gains, with most ...

DoP rejects Aristo Pharma’s review application for its multivitamin tablets: Gireesh Babu, New Delhi Friday, November 8, 2024, 08:00 Hrs [IST] The Department of Pharmaceuticals ...